Daebonglsco.,Ltd Logo

Daebonglsco.,Ltd

Develops and supplies raw materials for the pharmaceutical, cosmetic, and food industries.

078140 | KO

Overview

Corporate Details

ISIN(s):
KR7078140001
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도미래로 101 대봉그룹 송도 B&H Plex, 인천광역시

Description

Daebong LS is a specialized manufacturer and supplier of raw materials for the pharmaceutical, cosmetic, and food industries. The company focuses on enhancing quality of life through innovative and safe ingredients. It operates multiple research and development centers, including facilities specializing in natural products, biotechnology, and eco-friendly synthesis technologies. Daebong LS offers comprehensive solutions that cover the entire business cycle, from the development and production of raw materials to formulation, final product manufacturing, and clinical testing. The company's core activities are centered on developing advanced materials based on a deep understanding of medicine and a commitment to safety and innovation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
[기재정정]본점소재지변경
Korean 8.2 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-29 00:00
본점소재지변경
Korean 5.0 KB
2025-07-09 00:00
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-06-30 00:00
[기재정정]신규시설투자등
Korean 12.7 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-09 00:00
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-03-31 00:00
정기주주총회결과
Korean 27.7 KB
2025-03-21 00:00
감사보고서제출
Korean 25.6 KB
2025-03-21 00:00
사업보고서 (2024.12)
Korean 525.7 KB
2025-03-14 00:00
주주총회소집결의
Korean 14.0 KB
2025-03-14 00:00
주주총회소집공고
Korean 152.4 KB
2025-02-17 00:00
현금ㆍ현물배당결정
Korean 8.9 KB
2025-02-17 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2025-01-09 00:00
주식등의대량보유상황보고서(약식)
Korean 58.9 KB

Automate Your Workflow. Get a real-time feed of all Daebonglsco.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daebonglsco.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daebonglsco.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.